23andMe Investor Presentation Deck

>>> >>> >>> >>> Systematic, Scalable Research Platform Yields Novel Drug Targets Phenotypic Data Genetic Data 10,000s of Genome-Wide Association Study (GWAS) Hits Determine Disease Associated Genes and Directionality Translational Research to Understand Mechanism Identifying Druggable Targets Phenome-Wide Association Studies (PheWAS) Reveal Additional Indications and Potential Safety Concerns Assessment of Unmet Need and Competitive Landscape Best Drug Targets Wet lab validated targets progress through standard stages of research toward the selection of preclinical lead molecules and clinical development 23andMe's database yields thousands of GWAS hits Advanced biology and medicinal chemistry guide design of optimal compounds from initial targets Phenotypic breadth provides unique ability to uncover potential safety issues or possible indication expansions Copyright © 2022 23and Me, Inc. 23and Me 35

View entire presentation